- Home
- FAAS vs PRLD Comparison
FAAS vs PRLD Comparison
Compare FAAS & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAAS
- PRLD
- Stock Information
- Founded
- FAAS 2021
- PRLD 2016
- Country
- FAAS Indonesia
- PRLD United States
- Employees
- FAAS N/A
- PRLD N/A
- Industry
- FAAS
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FAAS
- PRLD Health Care
- Exchange
- FAAS NYSE
- PRLD Nasdaq
- Market Cap
- FAAS 48.2M
- PRLD 48.6M
- IPO Year
- FAAS N/A
- PRLD 2020
- Fundamental
- Price
- FAAS $0.49
- PRLD $0.82
- Analyst Decision
- FAAS
- PRLD Strong Buy
- Analyst Count
- FAAS 0
- PRLD 2
- Target Price
- FAAS N/A
- PRLD $4.50
- AVG Volume (30 Days)
- FAAS 5.8M
- PRLD 188.1K
- Earning Date
- FAAS 01-01-0001
- PRLD 08-11-2025
- Dividend Yield
- FAAS N/A
- PRLD N/A
- EPS Growth
- FAAS N/A
- PRLD N/A
- EPS
- FAAS N/A
- PRLD N/A
- Revenue
- FAAS $57,730,593.00
- PRLD $7,000,000.00
- Revenue This Year
- FAAS N/A
- PRLD N/A
- Revenue Next Year
- FAAS N/A
- PRLD N/A
- P/E Ratio
- FAAS N/A
- PRLD N/A
- Revenue Growth
- FAAS 38.16
- PRLD N/A
- 52 Week Low
- FAAS $0.16
- PRLD $0.61
- 52 Week High
- FAAS $3.50
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- FAAS 46.66
- PRLD 47.69
- Support Level
- FAAS $0.43
- PRLD $0.77
- Resistance Level
- FAAS $0.78
- PRLD $0.85
- Average True Range (ATR)
- FAAS 0.08
- PRLD 0.06
- MACD
- FAAS -0.01
- PRLD 0.00
- Stochastic Oscillator
- FAAS 25.81
- PRLD 38.83
About FAAS DIGIASIA CORP
DigiAsia Corp operates as a holding company. The majority of DigiAsia's operations are currently conducted through its majority-owned entities, controlled entities and corporate joint venture. It is among the first embedded fintech as a service (EFaaS) companies in Indonesia serving business-to-business-to-consumer (B2B2C) customers, such as large corporations and state-owned enterprises, as well as business-to-business (B2B) customers, such as micro, small and medium-sized enterprise (MSME) merchants, across various segments. It aims to be a fintech-enabling platform in Southeast Asia by accelerating financial inclusion through its licenses and technology stack and combining the benefits of technological innovation with traditional financial services.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.